References
Matsumoto K, Yano M, Miyake S, Ueki Y, Yamaguchi Y, Akazawa S, et al. Effects of voglibose on glycemic excursions, insulin secretion, and insulin sensitivity in non-insulin-treated NIDDM patients. Diabetes Care. 1998;21:256–60.
Kawamori R, Tajima N, Iwamoto Y, Kashiwagi A, Shimamoto K, Kaku K. Voglibose Ph-3 Study Group. Voglibose for prevention of type 2 diabetes mellitus: a randomised double-blind trial in Japanese individuals with impaired glucose tolerance. Lancet. 2009;373:1607–14.
Conflict of interest
None
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Yoshikawa, R., Hishinuma, R., Kaneko, H. et al. Agranulocytosis due to an α-glucosidase inhibitor, voglibose. Int J Diabetes Dev Ctries 35, 384–385 (2015). https://doi.org/10.1007/s13410-014-0242-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13410-014-0242-7